| Company Name: |
BOC Sciences |
| Tel: |
16314854226; +8616314854226 |
| Email: |
inquiry@bocsci.com |
|
| | BMS-192364 Basic information |
| Product Name: | BMS-192364 | | Synonyms: | BMS-192364;3H-1,2,4-Triazol-3-one, 2-(5-chloro-2-hydroxyphenyl)-1,2-dihydro-5-[4-(trifluoromethyl)phenyl]-;UNII-1NC8D8P7QF | | CAS: | 202822-21-7 | | MF: | C15H9ClF3N3O2 | | MW: | 355.7 | | EINECS: | | | Product Categories: | | | Mol File: | 202822-21-7.mol |  |
| | BMS-192364 Chemical Properties |
| form | Solid | | color | White to off-white |
| | BMS-192364 Usage And Synthesis |
| Uses | BMS-192364 is targeting the Gα-RGS interaction to produce an inactive Gα-RGS complex. BMS-192364 reduces urinary bladder contraction and exert RGS-agonist properties by increasing the action of GAPs on Gq proteins. BMS-192364 inhibits calcium flux[1][2][3]. | | References | [1] Kevin Fitzgerald, et al. Chemical genetics reveals an RGS/G-protein role in the action of a compound. PLoS Genet. 2006 Apr;2(4):e57. DOI:10.1371/journal.pgen.0020057 [2] Maciej Salaga, et al. RGS proteins as targets in the treatment of intestinal inflammation and visceral pain: New insights and future perspectives. Bioessays. 2016 Apr;38(4):344-54. DOI:10.1002/bies.201500118 [3] David P Basile, et al. A GAP in our knowledge of vascular signaling in acute kidney injury. Kidney Int. 2011 Aug;80(3):233-5. DOI:10.1038/ki.2011.145 |
| | BMS-192364 Preparation Products And Raw materials |
|